OLMA

OlemaC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

Current thesis

The constructive case is straightforward: the company has cash runway into mid-2028, OP-3136 data are due in Q2 2026, and the core equity unlock is OPERA-01 top-line data in fall 2026 with management already outlining a possible 2027 NDA and late-2027 launch path if the study works [#10-K-2026-03-16][#8-K-2026-03-16].

Posture

Mixed

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta -0.7.

What can break

Cash runway is projected through mid-2028, but higher trial/commercial-prep spending could pull financing needs forward if timelines slip.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $17.00 · Bull $26.00 · Bear $10.00

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $40.70

Why

Momentum19 · Δ7d +6.8

Value41 · Δ7d +0.0

Sentiment97 · Δ7d -0.7

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Sentiment · See AI snapshot

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

+6.8

Δ21d

+11.7

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendFlat

Δ7d

-0.7

Δ21d

-3.1

Why this grade

Composite grade C. Momentum 18.7 / Value 41.1 / Sentiment 96.6

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$991.39M

Beta

1.91

Shares Out

87.35M

P/E (TTM) · Derived

-6.1

P/S (TTM)

P/FCF (TTM) · Derived

-7.01

Rev YoY

EPS YoY

+45.2%

Gross Margin

Op Margin

Net Debt

-$501.24M

Current Ratio

10.88

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology